N@N

Vamil Divan Downgraded (TVTX) to Hold on, Mar 27th, 2024

Vamil Divan of Guggenheim, Downgraded "Travere Therapeutics, Inc." (TVTX) to Hold on, Mar 27th, 2024.

Vamil has made no other calls on TVTX in the last 4 months.

There are 6 other peers that have a rating on TVTX. Out of the 6 peers that are also analyzing TVTX, 3 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Mohit Bansal of "Wells Fargo" Maintained at Hold with Increased Target to $9 on, Friday, February 16th, 2024
• Nicole Gabreski of "Piper Sandler" Maintained at Hold with Increased Target to $11 on, Thursday, January 18th, 2024
• Alex Thompson of "Stifel" Maintained at Hold with Increased Target to $10 on, Monday, December 18th, 2023

These are the ratings of the 3 analyists that currently disagree with Vamil

---

• Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $17 on, Wednesday, March 13th, 2024
• Laura Chico of "Wedbush" Reiterated at Buy and Held Target at $13 on, Friday, February 16th, 2024
• Carly Kenselaar of "Citigroup" Upgraded from Hold to Strong Buy and Increased Target to $10 on, Tuesday, December 5th, 2023

Contributing Sources

---